Company profile
ProMIS Neurosciences Inc.
NASDAQ:PMNBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06105528 | phase1 | completed | 2023-11-18 | 2024-07-31 | ProMis Neurosciences, Inc | A Phase 1a Study of PMN310 In Healthy Volunteers |
| NCT06750432 | phase1 | active_not_recruiting | 2024-12-13 | 2026-12-01 | ProMis Neurosciences, Inc | PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) |
FDA applications (0)
No records yet.